InDex Pharmaceuticals has enrolled the first subject in the clinical pharmacokinetic (PK) trial of its drug candidate, cobitolimod, to locally treat colonic inflammation in individuals with ulcerative colitis (UC).
A Toll-like receptor 9 (TLR9) agonist, cobitolimod can potentially offer a local anti‐inflammatory effect in the large intestine, which could stimulate mucosal healing and relieve the clinical symptoms of UC.
The trial will assess the systemic uptake of the drug to treat colonic inflammation enrolling a minimum of six subjects with moderate to severe UC.
These patients will receive 500mg doses of cobitolimod given rectally.
The uptake of the drug will initially be measured in active UC individuals and subsequently in those who respond to the therapy.
The study is carried out parallelly with the international Phase III CONCLUDE trial of cobitolimod that will recruit nearly 440 subjects in more than 30 countries.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The randomised, placebo-controlled, double-blind CONCLUDE trial will assess the drug as a new therapy to treat people with moderate to severe left-sided UC.
Last month, InDex had enrolled the first subject in the trial.
In the Phase IIb CONDUCT trial, cobitolimod met the primary goal and showed robust efficacy and safety.
Furthermore, the results from four prior placebo-controlled trials support the efficacy and safety found in the CONDUCT trial.
InDex Pharmaceuticals CEO Peter Zerhouni said: “With the PK study, we aim to confirm the limited systemic uptake of cobitolimod shown in previous preclinical and clinical studies.
“This likely contributes to cobitolimod’s excellent safety profile and is a significant advantage compared to the current systemically administered drugs for ulcerative colitis that can cause severe off-target effects.”
UC is a chronic disease that causes large intestine inflammation.